Review decision – June 2018

Decision to move the existing guidance to the static list

Recent clinical evaluations of rifaximin suggest that it remains an effective treatment option in this patient population. No new evidence was identified that would substantially change the recommendations in TA337.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA337 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: